
Lifeclean Q4'23 - Focus on new agreements in 2024

Redeye saw a sales development that was better than our expectations. The sales development compared to last year's quarter was up 38%, with real sequential improvement. The volatility in sales is still considerable. We have adjusted our sales estimates for the future due to new agreements and positive end-of-year sales. The cost has been increased primarily for 2024e. We have increased our Base case to SEK 7.0 (6.7), including a new issue, per share, and our Fair value range to SEK 3.6 – 15 (3.3–13.6) per share.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Lifeclean Q4'23 - Focus on new agreements in 2024](#)